481 related articles for article (PubMed ID: 25921382)
1. Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial.
Gérard JP; Chamorey E; Gourgou-Bourgade S; Benezery K; de Laroche G; Mahé MA; Boige V; Juzyna B
Radiother Oncol; 2015 May; 115(2):246-52. PubMed ID: 25921382
[TBL] [Abstract][Full Text] [Related]
2. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
[No Abstract] [Full Text] [Related]
3. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.
Gérard JP; Azria D; Gourgou-Bourgade S; Martel-Laffay I; Hennequin C; Etienne PL; Vendrely V; François E; de La Roche G; Bouché O; Mirabel X; Denis B; Mineur L; Berdah JF; Mahé MA; Bécouarn Y; Dupuis O; Lledo G; Montoto-Grillot C; Conroy T
J Clin Oncol; 2010 Apr; 28(10):1638-44. PubMed ID: 20194850
[TBL] [Abstract][Full Text] [Related]
4. [Preoperative chemoradiotherapy for rectal cancer: experience from one centre].
Lescut N; Lepinoy A; Schipman B; Cerda T; Guimas V; Bednarek C; Bosset JF
Cancer Radiother; 2015 Apr; 19(2):98-105. PubMed ID: 25769650
[TBL] [Abstract][Full Text] [Related]
5. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.
Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V
J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J
J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339
[TBL] [Abstract][Full Text] [Related]
7. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
Dewdney A; Cunningham D; Tabernero J; Capdevila J; Glimelius B; Cervantes A; Tait D; Brown G; Wotherspoon A; Gonzalez de Castro D; Chua YJ; Wong R; Barbachano Y; Oates J; Chau I
J Clin Oncol; 2012 May; 30(14):1620-7. PubMed ID: 22473163
[TBL] [Abstract][Full Text] [Related]
8. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
9. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
Chua YJ; Barbachano Y; Cunningham D; Oates JR; Brown G; Wotherspoon A; Tait D; Massey A; Tebbutt NC; Chau I
Lancet Oncol; 2010 Mar; 11(3):241-8. PubMed ID: 20106720
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer.
Zhao L; Bai C; Shao Y; Guan M; Jia N; Xiao Y; Qiu H; Zhang F; Yang T; Zhong G; Chen S
Cancer Lett; 2011 Nov; 310(2):134-9. PubMed ID: 21782322
[TBL] [Abstract][Full Text] [Related]
11. Evolving role of neoadjuvant therapy in rectal cancer.
Schrag D
Curr Treat Options Oncol; 2013 Sep; 14(3):350-64. PubMed ID: 23828092
[TBL] [Abstract][Full Text] [Related]
12. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
Arbea L; Martínez-Monge R; Díaz-González JA; Moreno M; Rodríguez J; Hernández JL; Sola JJ; Ramos LI; Subtil JC; Nuñez J; Chopitea A; Cambeiro M; Gaztañaga M; García-Foncillas J; Aristu J
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):587-93. PubMed ID: 22079731
[TBL] [Abstract][Full Text] [Related]
13. Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: tolerance and efficacy.
François E; Azria D; Gourgou-Bourgade S; Jarlier M; Martel-Laffay I; Hennequin C; Etienne PL; Vendrely V; Seitz JF; Conroy T; Juzyna B; Gerard JP
Radiother Oncol; 2014 Jan; 110(1):144-9. PubMed ID: 24418359
[TBL] [Abstract][Full Text] [Related]
14. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
[TBL] [Abstract][Full Text] [Related]
15. Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group.
Hospers GA; Punt CJ; Tesselaar ME; Cats A; Havenga K; Leer JW; Marijnen CA; Jansen EP; Van Krieken HH; Wiggers T; Van de Velde CJ; Mulder NH
Ann Surg Oncol; 2007 Oct; 14(10):2773-9. PubMed ID: 17653805
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.
Gérard JP; Azria D; Gourgou-Bourgade S; Martel-Lafay I; Hennequin C; Etienne PL; Vendrely V; François E; de La Roche G; Bouché O; Mirabel X; Denis B; Mineur L; Berdah JF; Mahé MA; Bécouarn Y; Dupuis O; Lledo G; Seitz JF; Bedenne L; Juzyna B; Conroy T
J Clin Oncol; 2012 Dec; 30(36):4558-65. PubMed ID: 23109696
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
18. T3+ and T4 rectal cancer patients seem to benefit from the addition of oxaliplatin to the neoadjuvant chemoradiation regimen.
Martijnse IS; Dudink RL; Kusters M; Vermeer TA; West NP; Nieuwenhuijzen GA; van Lijnschoten I; Martijn H; Creemers GJ; Lemmens VE; van de Velde CJ; Sebag-Montefiore D; Glynne-Jones R; Quirke P; Rutten HJ
Ann Surg Oncol; 2012 Feb; 19(2):392-401. PubMed ID: 21792506
[TBL] [Abstract][Full Text] [Related]
19. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
[TBL] [Abstract][Full Text] [Related]
20. Planned organ preservation for early T2-3 rectal adenocarcinoma: A French, multicentre study.
Gérard JP; Barbet N; Gal J; Dejean C; Evesque L; Doyen J; Coquard R; Gugenheim J; Benizri E; Schiappa R; Baudin G; Benezery K; François E
Eur J Cancer; 2019 Feb; 108():1-16. PubMed ID: 30580125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]